• Tandem Diabetes Care recently expanded compatibility of its t:slim X2 insulin pump with Control-IQ+ technology to work with Abbott’s FreeStyle Libre 3 Plus CGM in five European countries, while a new competitor, Modular Medical, reported first patient use of its Pivot tubeless insulin patch pump.
• This combination of broader CGM integration and the entry of a tubeless rival founded by Tandem’s original pump inventor highlights both ecosystem expansion and rising competitive pressure in insulin delivery technology.
• We’ll now examine how this new CGM compatibility and the emerging tubeless competition might influence Tandem’s existing investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Tandem Diabetes Care Investment Narrative Recap

To own Tandem shares, you need to believe its pump ecosystem can stay relevant as diabetes care shifts toward automated and tubeless insulin delivery. The Libre 3 Plus integration supports the near term catalyst of international expansion, while Modular Medical’s tubeless Pivot pump reinforces the key risk that competition in both traditional and patch pumps could weigh on new starts and renewals. So far, the impact looks more sentiment driven than fundamentally transformative.

The Libre 3 Plus compatibility launch in five European countries ties directly into Tandem’s push to deepen international direct sales and broaden CGM choice. This update may help the company better monetize its existing installed base abroad and attract CGM-first users, which aligns with analysts’ focus on pharmacy channel expansion, recurring supplies, and higher-margin international revenue as central drivers of the story from here.

Yet behind this broader opportunity, investors should still watch how rising tubeless competition could affect...

Tandem Diabetes Care's narrative projects $1.4 billion revenue and $63.4 million earnings by 2029. This requires 10.3% yearly revenue growth and a $157.9 million earnings increase from -$94.5 million today.

Uncover how Tandem Diabetes Care's forecasts yield a $29.20 fair value, a 85% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting revenue near US$1.6 billion and earnings of about US$171 million by 2029, while also assuming that next generation tubeless and automated products unlock recurring upgrade cycles; this bullish view contrasts with the clear competition risks highlighted by Modular Medical’s Pivot launch and shows how your expectations on both growth and competitive intensity can meaningfully shift how you interpret today’s news.

Explore 3 other fair value estimates on Tandem Diabetes Care - why the stock might be worth just $29.20!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Tandem Diabetes Care research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Tandem Diabetes Care research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tandem Diabetes Care's overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 41 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.